Sebia acquires ZEUS Scientific

Sebia acquires ZEUS Scientific

The strategic acquisition reinforces Sebia's product portfolio & strategy in autoimmunity

Lisses, France, October 11, 2022 – Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announces the acquisition of  ZEUS Scientific, an In Vitro Diagnostic (IVD) company based in New Jersey (US) specialized in autoimmune and infectious diseases technologies. Financial terms of the agreement are undisclosed.

The state-of-the-art diagnostic company, ZEUS Scientific, will provide synergies and expand Sebia’s capabilities and product portfolio in autoimmunity, with a strong footprint in the United States.

“Through this acquisition, we will be able to expand Sebia’s capabilities to provide high-value solutions to our customers and patients,” said Jean-Marc Chermette, Sebia’s president and CEO.“ZEUS Scientific has developed a strong expertise in autoimmunity and infectious diseases. There are many parallels in our respective R&D programs, as well as benefits for the development of our global commercial network. With this acquisition, Sebia is reinforcing its operations and footprint in the United States, the largest IVD market. I am very pleased to welcome ZEUS Scientific associates to the Sebia Group and look forward to a strong collaboration to accelerate innovation and global growth.”

ZEUS Scientific is a global company focusing on the development, production and marketing of in vitro diagnostic tests to detect autoimmune and infectious diseases, available in several different technology applications. Clinical areas include inflammatory rheumatic diseases, serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology and a number of infectious diseases, with a strong focus on Lyme disease.

“We are extremely pleased to join the Sebia team,” said Scott Tourville, CEO of ZEUS Scientific. “Its world-leading position in clinical protein electrophoresis and in vitro diagnostic testing makes Sebia the ideal company to continue to build on Zeus Scientific’s 46-year legacy of diagnostic innovation.”

70% of medical decisions are based on laboratory tests results, including in vitro diagnostic tests. The global in vitro diagnostics market is projected to reach $113.1 billion by 2026 at a CAGR of 2.9%. The autoimmune disease diagnostics market was valued at around $1.1 billion in 2021 and is estimated to register over 6.6% CAGR between 2022 and 2030.

View full press release here: https://www.sebia.com/en-us/ressources/sebia-acquires-zeus-scientific/